Hematopoietic stem cells (HSC) are responsible for the generation of all mature blood cells throughout life. Clonal hematopoiesis (abbreviated herein as "CH") arises when a single HSC clonal lineage contributes disproportionately to the population of mature blood cells. Early indications of this phenomenon came from observations that the ratio of maternal to paternal X-chromosome inactivation is skewed in the blood of some otherwise healthy individuals, especially amongst the elderly [1] [2] [3] [4] . Skewing can be seen in all hematopoietic lineages, consistent with an origin in HSCs, but is most easily seen in nucleated cells of the myeloid lineage because they are short lived and require continuous replenishment from HSCs 5, 6 . Age-related CH does not arise from a simple depletion of HSCs, as the abundance of HSCs in human bone marrow actually increases in older people 7 .
Skewed X-inactivation also occurs in myeloid neoplasias, including acute myelogenous leukemia (AML), myelodysplastic syndromes and myeloproliferative disorders [8] [9] [10] [11] . In AML, genes encoding epigenetic regulators such as DNMT3A, ASXL1, IDH2 and TET2 tend to mutate early in the development of disease 12 . Mutations of these so-called "early genes" can persist in HSCs of patients in remission, creating reservoirs of pre-leukemic clones that can engender a relapse [13] [14] [15] [16] . Early gene mutations are also detectable in mature blood cells of AML patients and some subjects with skewed X-inactivation but ostensibly normal hematopoiesis 13, 16, 17 . The frequencies of the mutant alleles in these cases indicate that the mutant cells must have undergone clonal expansions, despite retaining a capacity to differentiate normally. This suggests that early myeloid neoplasia-associated mutations in HSCs can drive CH without an obvious phenotypic effect on mature blood cells. In this paper, we refer to genes and mutations that are suspected of promoting clonal expansion in CH as candidate drivers (CD). A provisional list of CD genes, comprised primarily of genes showing the characteristics of the early genes mentioned above, has been compiled by Steensma et al. 18 . Whole exome sequencing (WES) and candidate gene analyses have shown that low variant allele fraction (VAF) CD mutations indicative of CH are associated with increased all-cause mortality rates and risks of subsequent hematological malignancy 19, 20 . This prompted some investigators to propose that the presence of a CD mutation with a VAF above 2% constitutes an at-risk clinical entity and to consider how it might be managed appropriately 18 .
In most studies based on DNA sequencing, the detection of CH per se has been inexorably bound up with the detection of mutations in genes previously known to be involved in hematological
For personal use only. on December 13, 2017 . by guest www.bloodjournal.org From malignancies [19] [20] [21] [22] [23] . Until now, this has precluded formal tests of association between CD mutations and CH. In this study we utilize the observation that HSCs accumulate somatic mutations over their life history, most of which have no apparent effect on cellular phenotype 24 . Each HSC and its clonal descendants are therefore "barcoded" with a unique spectrum of mutations. If a particular clone becomes a substantial contributor to hematopoiesis, then its unique spectrum of mutations should be evident in the sequence of peripheral blood DNA. The proportion of mature blood cells derived from a particular barcoded HSC clone will (for heterozygous mutant loci) be equivalent to about twice the VAF. Using this method to detect CH does not rely on the detection of a CD mutation, but it does require an extensive amount of sequence data. Genovese et al. used a method like this on whole exome sequence data to show that CH can occur in elderly people without CD mutations being detected 19 . Similarly, Holstege et al. used this method to detect extreme CH without CD mutations in a 115 year old woman 25 .
We have sequenced the whole genomes of a substantial number of Icelanders 26 . Here we use the whole genome sequence (WGS) data to search for CH events by counting the number of low-VAF mutations present in peripheral blood. We find that CH is far more common in the elderly than has previously been demonstrated. In the majority of CH cases, no CD mutation was evident.
METHODS
Full details of the methods used are given in Supplemental Data, available on the Blood website.
Subject recruitment and phenotyping:
The study is based on WGS data from whole blood samples from 11,262 Icelanders participating in various disease projects at deCODE genetics. The study was authorized by the Icelandic National Bioethics Committee and the Data Protection Authority. All individuals gave informed consent. Subjects were excluded if they had a diagnosis of hematological malignancy in the Icelandic Cancer Registry before or within 6 months after blood draw.
Whole genome sequencing: DNA samples were isolated from whole blood and prepared for sequencing using TruSeq Nano or TruSeq PCR-free library kits (Illumina). Libraries were sequenced on Illumina GAIIx, HiSeq2000/2500 or HiSeq X instruments. SNPs and indels were called using GATK and GenotypeGVCFs 27 then annotated using Ensembl Variant Effect Predictor 28 .
For personal use only. on December 13, 2017 . by guest www.bloodjournal.org From Identification of mosaic somatic mutations: In order to differentiate mosaic somatic mutations from germline ones, we first restricted analysis to mutations that occurred only once in individuals of proven Icelandic ancestry. Due to the large size of our sample and the population structure of Iceland, germline variants are most likely to be observed more than once in our sample. We then imposed VAF restrictions to identify mosaic somatic mutations. Germline mutations can by chance have an observed VAF considerably less than 0.5. To control the false discovery rate stemming from germline mutations to less than 1%, we considered only singleton mutations with a VAF <0.2 as being somatic and mosaic. The lower frequency limit of detected somatic mutations was 0.1, as determined by the sensitivity of the variant caller. At least 3 independent reads containing a variant allele were required to call a somatic mutation. The spectrum of mosaic somatic mutations called was similar to what has been observed previously in AML 24, 29 (Supplemental Figure S1 ).
Definition of clonal hematopoiesis cases:
We counted the number of mosaic somatic mutations in each subject. The 99.5 th % quantile of the distribution of counts in subjects under 35 was 20 mutations.
Subjects with more than 20 mutations were defined as WGS-outliers. We took outlier status as evidence that the subject had CH.
Criteria for detection of CD mutations: For 18 CD genes on a list from Steensma et al. 18 , we included all high impact mutations and any missense mutation that had been reported in the Catalogue of Somatic 23 could have generated a case that meets our criteria for CH.
WGS-based genome-wide association for inherited variants: Long-range haplotype phasing and genotype imputation was done as described previously [30] [31] [32] . This permitted us to reliably test for association with germline variants down to a minor allele frequency of about 0.05%.
Telomere length assay:
Estimates of telomere length were obtained from WGS data using TelSeq software 33 .
Statistical analysis: Analyses were performed using R packages including packages survival and ggplot2. For modelling of clonal hematopoiesis, the model of 34 was adapted to our data. Details of all analyses are presented in the Supplemental Data.
RESULTS

Clonal hematopoiesis is very common in the elderly
We generated WGS from 11,262 people to an average sequencing depth of 35.6 (median 34.8, range 20.4-119.2). We identified 3,300,768 singleton SNPs of which 146,389 were classified as mosaic somatic mutations. The Icelandic genealogy was used to ensure that none of the mosaic somatic mutations were transmitted in the germline (see Supplemental Data, Supplemental Figure S2 ). The mean VAF of the mutations was 0.17 with a range of 0.11-0.20. The upper boundary was set to control the false discovery rate due to interference from constitutional mutations to a level of less than 1%, whereas the lower boundary was determined by the sensitivity of the variant caller. As shown in Figure 1a , younger subjects showed a distribution with a median of around 3 mosaic somatic mutations. Above an age of 35 to 45 years, the number of people with a high count of mosaic somatic mutations climbed rapidly. We applied a cutoff of >20 mosaic somatic mutations (corresponding to the 99.5 th % quantile of the distribution for ages under 35) to classify individuals as "WGS-outliers" (Supplemental Table 2 ). We took WGS-outlier status as evidence that the person had CH. By this criterion, 1,403 subjects out of
For personal use only. on December 13, 2017. by guest www.bloodjournal.org From 11,262 had CH, a prevalence of 12.5% over all age groups. The frequency of WGS-outliers increased from 0.5% (by definition) in subjects younger than 35 years to more than 50% for subjects older than 85 years ( Figure 1a ,b). This peak prevalence is more than twice that of previous estimates made using WES data 19, 20 . Hence, it appears that CH is far more common amongst the elderly than has previously been
shown. This confirms a prediction by McKerrell et al. that CH would prove to be an almost inevitable consequence of advanced aging 21 .
To align our analysis with what might be detected by WES, we restricted the scope to mosaic somatic mutations that occurred in exons. Only 176 subjects were then detected as outliers (see Supplemental Data), 174 of whom had already been identified as WGS-outliers. The exome-restricted detection rate corresponded to 12.4% of the 1,403 CH cases detected as WGS-outliers ( Figure 1b ). These 174 people had a 2.65-fold higher number of mosaic somatic mutations as measured by WGS (mean number 138 vs 52, P =2.8x10 -81 ) and were on average 7.8 years older than other WGS-outliers (P =1.2x10 -7 ). The agespecific prevalence of outliers detected by exon-restricted analysis was similar to published estimates using WES (Figure 1b ) 19, 20 . Thus, the WGS-outlier method offers much greater sensitivity for detection of CH than exome-restricted methods.
Association of driver mutations with clonal hematopoiesis
We investigated what proportion of our CH cases carries detectable mosaic somatic mutations in CD genes. As candidates, we used a list of 18 CD genes that have previously been seen mutated in myeloid neoplasia 18 . The list also includes PPM1D which was never implicated in hematological malignancy but shows somatic mutation in blood in association with breast cancer, ovarian cancer and prior chemotherapy [35] [36] [37] [38] . For detection of CD mutations we used a different strategy from the one used to detect barcode mutations. We permitted somatic mutations that were present in more than one individual and at a wider range of VAFs (see Supplemental Data). We found 286 CD mutations in 16 of the genes in 246 out of 11,262 people ( Supplemental Table 2 ). For 196 individuals, their CD mutation occurred in either DNMT3A (n=93), TET2 (n=76), ASXL1 (n=25) or PPM1D (n=18). The probability of detection of a CD mutation was strongly dependent on age (Figure 1b) . Subjects with CD mutations were on average 18 years older than those without (P =2x10 -46 ). The age-specific prevalence of CD mutations was in line with what has been observed previously using WES 19, 20 . However, mutations in the 18 CD genes were detected in only a small proportion of CH cases (12.6%, 177/1403, Figure 1b) .
Employing a less
For personal use only. on December 13, 2017. by guest www.bloodjournal.org From stringent criterion to define CD mutations ("COSMIC5", see Supplemental Data) explained a further 9 CH cases ( Supplemental Table 2 ). Analysis of sample subsets for CNV resulting in deletions of CD genes, recurrent AML fusion genes, or for mutations detected by high depth WGS did not yield substantial numbers of additionally explained CH cases (Supplemental Data and Figure S3 , Supplemental Table 4 ). We then employed deep resequencing of a panel of amplicons from 54 genes frequently mutated in myeloid malignancies, as well as PPM1D, on 76 CH cases selected by stratified random sampling. The method allowed us to detect mutations reliably down to a VAF of 0.01 (i.e. approximately 10-fold lower than the lower limit of WGS-outlier barcode mutations). We found CD mutations in 30 of the 76 cases (39.5%) who were resequenced (Supplemental Table 3 ). Adding the estimated 1.2% of cases who have a large deletion of a CD gene (Supplemental Data, Figure S3 ), this corresponds to 40.7% of WGS-outliers who might plausibly be accounted for by a CD mutation detectable by our methods. This is likely to be an over-estimate, however, because some of the observed CD mutations may not have a sufficiently high VAF to account for the clone generating the associated WGS-outlier barcode (see Supplemental Data). In any case, the majority of our CH cases remain in need of a satisfactory mechanistic explanation. Tables 2 and 3 ). We speculated that some younger people who have CH with CD mutations might not have been detected as WGS-outliers because they had not accumulated enough mosaic somatic mutations to qualify. Indeed, the fraction of subjects with a CD mutation who were also WGS-outliers increased significantly with age (P=1.9x10 -12 , Figure 2b ). DNMT3A, TET2 and ASXL1 were the genes most commonly mutated in both WGS-outliers and non-outliers (Figure 2c ). So, despite its high positivity rate in older people, the WGS-outlier method is still likely to under-report CH amongst the young.
Unlike previous studies, our WGS-outlier method defines CH cases irrespective of whether or not they have a mutation in a CD gene. Therefore, we could carry out unbiased tests of whether the presence of a mutant CD gene is associated with CH status. As shown in 
CH is associated with higher death rates and increased risks of hematological malignancy
Subjects with CH defined by WGS-outlier status had significantly higher rates of all-cause mortality (hazard ratio [HR] 1.18, P =2.7x10 -4 , Figure 3a) . WGS-outliers with or without detected CD mutations had similar risks. Subjects who had CD mutations were also at increased risk, irrespective of WGSoutlier status (HR =1.30, P =0.0042). To set the increased mortality rates in perspective, we found that smoking (ever) had an HR of 1.19 (P =2.6x10 -5 ). Therefore, the effect of clonal hematopoiesis on mortality rate is similar to ever smoking.
We also assessed the risk of a hematological malignancy arising 6 months or more after sampling (Figure 3b) . CH defined by WGS-outlier status substantially increased the risk of a subsequent hematological malignancy (HR =2.43, P =9.0x10 -5 ). Again, WGS-outliers with or without detected CD mutations had similar risks and all subjects with CD mutations were at increased risk. We noted that the risk increased with count of mosaic somatic mutations to HR =42.2 (P =1.3x10 -9 ) in subjects with over 250 mutations. This might be indicative of disease risk associated with the age (in divisions) of the HSC clone when it began to expand, its rate of expansion, its degree of predominance in supporting hematopoiesis (as the number of detected mutations is correlated with VAF) or the probability that a 1 0 leukemic driver gene had been hit by a mutation. Alternatively it might indicate that individuals with very high mutation counts have an undiagnosed, non-HSC hematological malignancy.
Association of CH with other phenotypes
We tested for association between the WGS-outlier status and 1,482 case:control phenotypes from the deCODE database (Supplemental Table 7 ). After consideration of a Bonferroni correction threshold (P < 3.4x10 -5 ), significant associations were found with Smoking (P =6.0x10 -13 ), Treatment for Addiction ), lymphocytes (P =6.4x10 -8 ), granulocytes (P =6.8x10 -6 ) and an increase in total platelet volume (P =7.8x10 -10 , Supplemental Table 8 ).
Mosaic loss of the Y chromosome is reportedly similar to CH in its age and phenotypic associations [39] [40] [41] .
Mosaic loss-of-Y showed a highly significant association with CH in our WGS data (P =5.02x10 -110 ) and had a similar age distribution (Supplemental Data, Figure S4 ). This suggests that mosaic loss-of-Y and CH are related phenomena.
Modelling clonal hematopoiesis due to neutral drift
The lack of identified CD mutations in most of the WGS-outliers led us to question whether such cell dynamics 34 adapted to our data (see Supplemental Data). Simulations with a plausible set of parameters indicated that clonal expansion could occur so rapidly by neutral drift that a substantial proportion of the WGS-outliers without known CD mutations would be explained (Figure 4 ). Neutral drift should therefore be considered as one possible mechanism underlying CH.
We noted that the simulations were very sensitive to N , the assumed size of the active HSC pool ( Figure   4 ). Estimates for the size of this pool vary widely [43] [44] [45] . The model was also sensitive to the value of p , the probability that a given cell division will produce two daughter stem cells. While a high Figure S5) . In other words, a
person with an endogenously high p could be predisposed to develop CH early through neutral drift.
Association of germline TERT variants with CH
To examine further the concept of constitutive predisposition to CH, we carried out a WGS-based genome-wide association study for germline SNPs and small indels 26 , using WGS-outlier status as the query phenotype. The strongest association came from an 8bp deletion in intron 3 of the telomerase reverse transcriptase (TERT) gene (rs34002450, g.1280826_1280833delAGCCCACC, P = 7.4x10 -12 , OR = 1.37, allele frequency = 40.6% in Iceland, Figure 5 ). Previously, we reported an association between myeloproliferative neoplasms (MPN) and a common variant in TERT (rs2736100, r 2 = 0.28 vs rs34002450) 46 . Conditional analysis showed that the CH association mapped preferentially to rs34002450 (P adj = 3.6x10 -8 ) whereas the MPN association mapped preferentially to rs2736100 (P unadj = 2.2x10 -8 , P adj = 6.4x10 -4 ). Rare coding mutations in TERT have been implicated in marrow failure and HSC dysfunction 47, 48 . In our study, no high or moderate impact germline variants (with CH-association P values of <0.05 and <2.5x10 -3 , respectively) were seen in TERT or any of the 18 CD genes.
The TERT association suggested that telomerase activity might have a role in CH. To explore this further, we estimated telomere lengths for 2,703 samples based on the occurrence of the telomeric TTAGGG motif in WGS reads (see Supplemental Data). Telomere length estimates were significantly lower in people with CH defined by WGS-outlier status (β = -0.19 standard deviations, P =1.0x10 -3 ).
The presence of CD mutations had no effect in addition to WGS-outlier status. Moreover, we could detect no effect of the rs34002450 deletion on telomere length (P =0
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sex, age at blood draw, COPD, cancer diagnoses and smoking). Both telomere length and rs34002450 genotype were significant independent predictors of WGS-outlier status in a multivariate regression (P= 0.008 and 0.003 respectively, adjusted for age at blood draw and smoking). The involvement of TERT and telomere length with CH merits further investigation. Moreover, studies that ascribe phenotypic effects to variations in telomere length should consider a possible role of CH.
DISCUSSION
Using whole genome sequence data from peripheral blood of 11,262 people, we have developed a method to identify individuals with CH based on the accumulation of somatic mutations in the dominant HSC clone. Unlike previous studies of CH, this method does not depend on prior knowledge of CD genes or mutations. We detected a high prevalence of CH amongst the elderly, trending towards inevitability.
Holstege et al. 25 studied WGS of a 115 year old woman with extreme CH and found no CD mutations (nor indeed any mutations present in the COSMIC catalogue). This suggested that CH might occur in the absence of detectable CD mutations. Similarly, Genovese et al. 19 , using WES, did not detect CD mutations in a substantial fraction of their CH subjects. In our study, we did not find obvious CD mutations in the majority of subjects with WGS-outlier status indicative of CH. Conceivably, the lack of identified CD mutations could be due firstly to a simple inability to detect them with the methods applied. Our sensitivity to detect a driver mutation might be rather limited for clones with low degrees of predominance and high mutation burdens. Secondly, due to genetic heterogeneity, each individual driver mutation might occur at too low a frequency in the CH population to be recognized as such, or be located in a non-exonic region. Thirdly, CH could be driven by variation in clonally inherited epigenetic states that affect the self-renewal and proliferative capacities of HSCs 49 . Fourthly, some CH may be a simple (or indeed, inevitable) consequence of neutral drift operating on the small, ageing population of active HSCs 42 . If this latter scenario is true, then it begs the question of why CH without defined CD mutations still carries high hazards of hematological malignancy and all-cause mortality, as we and others 19 have seen. Perhaps some instances of CH are indications that the HSC compartment is in a permissive state which allows clonal expansions to occur over short time scales. The situation may be akin to melanoma, where a high number of benign nevi is a strong risk factor even though few nevi progress to melanoma 50 .
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The ability to identify CH cases presents opportunities for monitoring and intervention. A number of authors have recommended the development of strategies to target and eliminate clonal reservoirs of HSCs containing pre-leukemic mutations 13, 15, 16, 18 . Such strategies must take into account that CH appears to be quite common in elderly asymptomatic individuals and that absolute risks of progression to hematological malignancy are low. Based on the observations described here, targeting known preleukemic driver mutations may address only a fraction of the at-risk individuals. Moreover, some people may be reliant on surviving mutant HSC clones to support their normal hematopoiesis and this may be associated with a general frailty. Clearly a deeper understanding of the nature and associated risks of clonal hematopoiesis would be valuable. Table 5 For personal use only. on December 13, 2017. by guest www.bloodjournal.org From Hazard ratios for all-cause mortality adjusted for age at blood draw, year of birth, sex, previous diagnoses of cancer and smoking. (B) Hazard ratios for subsequent hematological malignancy adjusted for age at blood draw and year of birth. Details of the subjects who developed hematological malignancies are shown in Supplemental Table 6 . For personal use only. on December 13, 2017 . by guest www.bloodjournal.org From Figure 1 For personal use only. For personal use only.
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